Explore the growing list of confirmed MSS2026 speakers and their topics, highlighting new approaches and current research in bioprocessing and related fields. This list is set to grow as additional speakers are confirmed. We invite you to register and submit your abstract for presentation to join this esteemed group of prominent speakers. Be part of the conversation and contribute to the future of science and technology.
Just Added
A Long-Term Perspective on AAV Gene Therapy
Robert Kotin (Massachusetts Institute of Technology, USA)
Beyond the sequence: how intended use shapes the regulatory pathway
Florence Salmon (Roche, Switzerland)
Applications of highly functional Xenoligo ssDNA aptamer technology for medical and bioprocessing
Miyuki Hori (TAGCyx Biotechnologies, Japan)
Digital twins of disease evolution to understand disease and its treatment ahead of time
Janez Štrancar (Infinite Biotech, Slovenia)
Long and winding road to scalability and clinical viability of Extracellular Vesicle–based therapies
Nataša Zarovni (RoseBio, Italy)
Enabling Scalable Chromatography from Analytical to Preparative Purification for LNPs
John McHale (Arcturus, USA)
Impact of Genome Fragmentation and Empty Capsids on rAAV Functional Potency in Liver Cells
David Dobnik (National Institute of Biology, Slovenia)
Evaluation of PrimaS and PrimaT Monolithic Chromatography Columns for Purification of Therapeutic Bacteriophages Targeting ESKAPE Pathogens
Danish J. Malik (Loughborough University, UK)
Enzymatically Synthesized DNA Templates Enable Scalable mRNA manufacture and Robust PolyA Tail Integrity
Stella Kounadi (4basebio, UK)
Multi-column chromatography for in situ production and purification of mRNA
Mark Stoops (BTEC, University NC, USA)
Native Elution Immunoaffinity Chromatography for Efficient Purification of Vesicular Stomatitis Virus
Adela Štimac (University of Zagreb, Croatia)
Ex tempore Oncolytic Virus Manufacturing: A Feasibility Assessment
Beata Halassy (University of Zagreb, Croatia)
Complete Lineup
A Long-Term Perspective on AAV Gene Therapy
Robert Kotin (Massachusetts Institute of Technology, USA)
Beyond the sequence: how intended use shapes the regulatory pathway
Florence Salmon (Roche, Switzerland)
Applications of highly functional Xenoligo ssDNA aptamer technology for medical and bioprocessing
Miyuki Hori (TAGCyx Biotechnologies, Japan)
Digital twins of disease evolution to understand disease and its treatment ahead of time
Janez Štrancar (Infinite Biotech, Slovenia)
Long and winding road to scalability and clinical viability of Extracellular Vesicle–based therapies
Nataša Zarovni (RoseBio, Italy)
Enabling Scalable Chromatography from Analytical to Preparative Purification for LNPs
John McHale (Arcturus, USA)
Impact of Genome Fragmentation and Empty Capsids on rAAV Functional Potency in Liver Cells
David Dobnik (National Institute of Biology, Slovenia)
Evaluation of PrimaS and PrimaT Monolithic Chromatography Columns for Purification of Therapeutic Bacteriophages Targeting ESKAPE Pathogens
Danish J. Malik (Loughborough University, UK)
Enzymatically Synthesized DNA Templates Enable Scalable mRNA manufacture and Robust PolyA Tail Integrity
Stella Kounadi (4basebio, UK)
Multi-column chromatography for in situ production and purification of mRNA
Mark Stoops (BTEC, University NC, USA)
Native Elution Immunoaffinity Chromatography for Efficient Purification of Vesicular Stomatitis Virus
Adela Štimac (University of Zagreb, Croatia)
Ex tempore Oncolytic Virus Manufacturing: A Feasibility Assessment
Beata Halassy (University of Zagreb, Croatia)
Non-viral, polymeric nanoparticle gene therapy for ocular disorders
Niren Shah and Andrew Knudten (Cove Therapeutics, USA)
tLNP as a novel gene therapy vector to deliver DNA – are we there yet?
Jacek Lubelski (NanoCell, Netherlands)
Away from Cohn, away from EtOH, the next generation plasma fractionation process
Aleš Štrancar (BIA Separations Inc, USA)
Monoliths in plasma fractionation – new trends and perspectives
Djuro Josić (Juraj Dobrila University of Pula, Croatia)
A comprehensive manufacturing and characterization approach to passive or active targeted LNP-based biopharmaceuticals
Tristan Kovačič (Sartorius BIA Separations, Slovenia)
Monolith-based immobilized enzyme reactors: enabling technologies for diverse and evolving landscapes
Manuela Bartolini (Alma Mater Studiorum University of Bologna, Italy)
Advancing biomanufacturing education: adapting workforce development for the next generation of biologics
Gary Gilleskie (Biomanufacturing Training and Education Center (BTEC), USA)
The RNA revolution: from novel vaccines to therapeutic genome editing
Dan Peer (Laboratory of Precision Nanomedicine, Tel Aviv University, Israel)
Purification of plasma derived therapeutic proteins using monolithic continuous annular chromatography
Yow-Pin Lim (ProThera Biologics Inc, USA)
Fighting CTNNB1 syndrome with AAV gene therapy: a mission to change the world
Špela Miroševič (CTNNB1 Foundation, Slovenia)
Chromatographic LNP purification for enhanced purity and activity in CRISPR, CAR-T, and vaccine manufacturing
Mojca Tajnik Sbaizero (Sartorius BIA Separations, Slovenia)
Commercial-Scale Evaluation of a CIMmultus® Mixed-Mode Monolith for IgG Production
Andre Germishuizen (National Bioproducts Institute (NBI), South Africa)
Interferon-inducing viral vector immunotherapy reprograms tumor immunity and eliminates persistent HPV infection
Thomas Muster (BlueSky Immunotherapies, Austria)
Affinity and mixed-mode convective adsorbents for the purification and enrichment of vectors for cell and gene therapies
Stefano Menegatti (North Carolina State University, USA)